-+ 0.00%
-+ 0.00%
-+ 0.00%

KARYOPHARM'S PHASE 3 SENTRY TRIAL IN MYELOFIBROSIS SELECTED FOR LATE-BREAKING ORAL PRESENTATION AT ASCO 2026 ANNUAL MEETING

Reuters·04/21/2026 14:32:58

Please log in to view news